RBC Capital analyst Gregory Renza downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Sector Perform and raises the price target from $60 to $68.5.
Equillium Announces Initiation Of Phase 2 Study Of EQ101 A First-in-Class Multi-Cytokine Inhibitor Of IL-2, IL-9 And IL-15 Targeting Alopecia Areata
Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has
